BR112015023571A2 - derivados de sulfamato e sulfamida de arila como moduladores rorc - Google Patents

derivados de sulfamato e sulfamida de arila como moduladores rorc

Info

Publication number
BR112015023571A2
BR112015023571A2 BR112015023571A BR112015023571A BR112015023571A2 BR 112015023571 A2 BR112015023571 A2 BR 112015023571A2 BR 112015023571 A BR112015023571 A BR 112015023571A BR 112015023571 A BR112015023571 A BR 112015023571A BR 112015023571 A2 BR112015023571 A2 BR 112015023571A2
Authority
BR
Brazil
Prior art keywords
sulfamate
sulfamide derivatives
modulators
compounds
aryl
Prior art date
Application number
BR112015023571A
Other languages
English (en)
Inventor
Fauber Benjamin
Bodil Van Niel Monique
Rene Olivier
Ward Stuart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015023571A2 publication Critical patent/BR112015023571A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1/1 resumo derivados de sulfamato e sulfamida de arila como moduladores rorc compostos da fórmula i: ou sais farmaceuticamente aceitáveis dos mesmos; em que m, n, p, q, r, a, x1, x2, x3, x4, x5, x6, y, z, g, r1a, r2a, r1b, r2b, r3, r4, r5 e r6 são como definido aqui. são também revelados métodos de fazer os compostos e usar os compostos para tratamento de doenças inflamatórias como artrite.
BR112015023571A 2013-03-15 2014-03-12 derivados de sulfamato e sulfamida de arila como moduladores rorc BR112015023571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790271P 2013-03-15 2013-03-15
PCT/EP2014/054764 WO2014140059A1 (en) 2013-03-15 2014-03-12 ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS

Publications (1)

Publication Number Publication Date
BR112015023571A2 true BR112015023571A2 (pt) 2017-07-18

Family

ID=50241444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023571A BR112015023571A2 (pt) 2013-03-15 2014-03-12 derivados de sulfamato e sulfamida de arila como moduladores rorc

Country Status (11)

Country Link
US (1) US8912219B2 (pt)
EP (1) EP2970116A1 (pt)
JP (1) JP2016510781A (pt)
KR (1) KR20150128863A (pt)
CN (1) CN105121404A (pt)
BR (1) BR112015023571A2 (pt)
CA (1) CA2902252A1 (pt)
HK (1) HK1218114A1 (pt)
MX (1) MX2015011180A (pt)
RU (1) RU2015141592A (pt)
WO (1) WO2014140059A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082533A1 (en) * 2013-12-05 2015-06-11 Lead Pharma Cel Models Ip B.V. Ror gamma (rory) modulators
RU2016131363A (ru) * 2014-01-10 2018-02-16 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ АРИЛСУЛЬТАМА В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРФАННОГО РЕЦЕПТОРА γ, СВЯЗАННОГО С РЕТИНОЕВОЙ КИСЛОТОЙ
WO2017005668A1 (en) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
WO2018185675A1 (en) * 2017-04-04 2018-10-11 Glenmark Pharmaceuticals S.A. Substituted oxoazetidine analogues as ror gamma modulators
JP2020536863A (ja) 2017-10-06 2020-12-17 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０の阻害
CN109896998B (zh) * 2017-12-10 2022-06-07 复旦大学 一种3,4-二氢异喹啉磺酰胺类化合物及其应用
MX2020012180A (es) 2018-05-17 2021-01-29 Forma Therapeutics Inc Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
CN113166108A (zh) 2018-10-05 2021-07-23 福马治疗有限公司 作为泛素特异性蛋白酶30(usp30)抑制剂的稠合吡咯啉
CN113336655A (zh) * 2020-12-30 2021-09-03 江西迪赛诺制药有限公司 一种(r)-3-氨基丁醇的制备方法
CN113013491A (zh) * 2021-03-16 2021-06-22 广州天赐高新材料股份有限公司 电解液添加剂、电解液及锂离子电池
CN113861045B (zh) * 2021-10-25 2024-06-07 绍兴众昌化工股份有限公司 一种(r)-3-氨基丁醇的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693372A1 (en) * 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Novel Sulfamides and their use as endothelin receptor antagonists
AU2003224030B2 (en) * 2002-04-03 2007-11-01 Novartis Ag 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as PTPase 1B inhibitors
AU2003256755A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
EP1673085B1 (en) * 2003-09-26 2011-11-09 Exelixis, Inc. C-met modulators and methods of use
JP2006083137A (ja) * 2004-09-17 2006-03-30 Sankyo Co Ltd 免疫抑制剤
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2008042867A2 (en) * 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
WO2008109154A1 (en) * 2007-03-08 2008-09-12 Altiris Therapeutics, Inc. Chemokine receptor modulators
WO2010029048A1 (en) * 2008-09-09 2010-03-18 Sekmed Srl 1, 2, 5-thiadiazole derivatives useful as immune potentiators
CA2759482A1 (en) * 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
GB201002563D0 (en) * 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
CN103209960A (zh) * 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
US9512111B2 (en) * 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
PT2704721T (pt) * 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
US9586928B2 (en) * 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR

Also Published As

Publication number Publication date
EP2970116A1 (en) 2016-01-20
KR20150128863A (ko) 2015-11-18
RU2015141592A (ru) 2017-04-21
US8912219B2 (en) 2014-12-16
MX2015011180A (es) 2015-11-11
WO2014140059A1 (en) 2014-09-18
JP2016510781A (ja) 2016-04-11
US20140275032A1 (en) 2014-09-18
CN105121404A (zh) 2015-12-02
CA2902252A1 (en) 2014-09-18
HK1218114A1 (zh) 2017-02-03

Similar Documents

Publication Publication Date Title
BR112015023571A2 (pt) derivados de sulfamato e sulfamida de arila como moduladores rorc
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1119531T1 (el) Ενωσεις και συνθεσεις για την ρυθμιση της δραστηριοτητας toy egfr
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112015013485A2 (pt) derivados de benzilsulfonamida como moduladores de rorc
CY1124537T1 (el) Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
BR112014010813A2 (pt) n-(tetrazol-5-il)-aril-carboxamidas e n-(triazol-5-il)-aril-carboxamidas substituídas em 5-fenilo e sua utilização como herbicidas
BR112016015717A8 (pt) macrociclos com grupos p2' heterocíclicos como inibidores do fator xia
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112018006034A2 (pt) compostos bicíclicos como inibidores de atx
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA201892264A1 (ru) Производные тетрагидроизохинолина
BR112019003897A2 (pt) aminopirimidinas como inibidores de alk
CY1118371T1 (el) Αναστολεις του iap
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
MX2016008499A (es) Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc).
BR112012017277A2 (pt) Compostos e métodos
MX2019011774A (es) N-(-1,3,4-oxadiazol-2-il)arilcarboxamidas sustituidas y su uso como herbicidas.
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.